Myopia
Conditions
Interventions
A group:Wear non-periodic tessellated microstructure (Guangyin Control) lenses for 12 months.
B group:Wear multi-zone positive optical defocus design lenses for 12 months.
C group:Wear aspheric single-vision lenses for 12 months.
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
8 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. Able to understand and participate in the consent process, accompanied by a parent or guardian who can read and understand Chinese, and sign the informed consent/consent statement; 2. Age 8-12 years at enrollment, of any gender; 3. Diagnosed with myopia, with cycloplegic objective computerized refractive spherical equivalent between -0.75D and -4.00D (inclusive of -0.75D and -4.00D); 4. Absolute value of astigmatism <=2.00D; 5. Anisometropia (based on cycloplegic objective computerized refractive spherical equivalent) <=1.50D; 6. Corrected visual acuity in each eye equal to or better than decimal visual acuity 0.8 (LogMAR 0.1); 7. Willing to wear the trial lenses as required by the investigator (full-time wear, not less than 10 hours per day), and complete scheduled visits as planned.
Exclusion criteria
Exclusion criteria: 1. Any active ocular disease and systemic diseases affecting the eyes (such as diabetes, Graves' disease, ankylosing spondylitis, multiple sclerosis, Sjogren's syndrome, systemic lupus erythematosus, etc.); 2. Use of or currently using products that slow myopia progression within the past month, including specially designed frame glasses, specially designed RGP lenses, specially designed soft contact lenses, and progressive frame glasses; 3. Use of or currently using OK lenses or atropine drugs within the past three months; 4. Have used or currently using red light or other optical therapy devices; 5. Currently using or during the follow-up research need to use drugs that may cause dry eye or affect vision (such as penicillin, streptomycin, chloramphenicol, sulfonamides, isoniazid, etc.); 6. Known allergy to components of cycloplegic eye drops (obucaine, proparacaine, or tropicamide); 7. Manifest strabismus or obvious binocular vision abnormalities; 8. Currently participating in other clinical trials; 9. Abnormalities in slit-lamp examination, fundus examination, or intraocular pressure examination with clinical significance; 10. Ocular and systemic abnormalities that may affect visual function or refractive development; 11. Other situations deemed by the researcher as unsuitable for participation in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Axial length;Cycloplegic refraction; | — |
Secondary
| Measure | Time frame |
|---|---|
| corrected visual acuity with spectacles;visual function; | — |
Countries
China
Contacts
Public ContactKai Wang
Peking University People's Hospital
Outcome results
None listed